Population Based Analysis Ependymoma Patients in Alberta from 1975 to 2007

AbstractBackground: Ependymomas are rare tumors of the central nervous system whose management is controversial. This population-based study of adults and children with ependymoma aims to (1) identify clinical and treatment-related factors that impact survival and (2) determine if postoperative radiotherapy (RT) can improve survival of patients with subtotal resection (STR) to levels similar to patients who had gross total resection (GTR). Methods: This retrospective population-based study evaluated 158 patients with ependymoma diagnosed between 1975-2007 in Alberta, Canada. Results: Younger patients (<7 years of age) were more likely to be diagnosed with grade III tumors compared with adults in whom grade I tumors were more common (p=0.003). Adults were more likely to have spinally located tumors compared to young children whose tumors were typically found in the brain. Overall, young children with ependymoma were more likely to die than older children or adults (p=0.001). An equivalent number of patients underwent GTR as compared with STR (48% vs 45%, respectively). Overall, older age, spinal tumor location, lower grade, and GTR were associated with improved progression free survival but only GTR was associated with significant improvement in overall survival. Median survival after STR and RT was 82 months compared with 122 months in patients who had GTR (p=0.0022). Conclusions: This is the first Canadian population-based analysis of patients with ependymoma including adults and children. Extent of resection appears to be the most important factor determining overall survival. Importantly, the addition of RT to patients initially treated with STR does not improve survival to levels similar to patients receiving GTR.

Download Full-text

Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada

Cancers ◽

10.3390/cancers13112844 ◽

2021 ◽

Vol 13 (11) ◽

pp. 2844

Author(s):

Christopher J. D. Wallis ◽

Bobby Shayegan ◽

Scott C. Morgan ◽

Robert J. Hamilton ◽

Ilias Cagiannos ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Clinical Decision Making ◽

Cox Regression ◽

De Novo ◽

Population Based ◽

Population Based Study ◽

Cox Regression Analysis ◽

Lymphocyte Ratio ◽

Laboratory Markers

De novo cases of metastatic prostate cancer (mCSPC) are associated with poorer prognosis. To assist in clinical decision-making, we aimed to determine the prognostic utility of commonly available laboratory-based markers with overall survival (OS). In a retrospective population-based study, a cohort of 3556 men aged ≥66 years diagnosed with de novo mCSPC between 2014 and 2019 was identified in Ontario (Canada) administrative database. OS was assessed by using the Kaplan–Meier method. Multivariate Cox regression analysis was performed to evaluate the association between laboratory markers and OS adjusting for patient and disease characteristics. Laboratory markers that were assessed include neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), albumin, hemoglobin, serum testosterone and PSA kinetics. Among the 3556 older men with de novo mCSPC, their median age was 77 years (IQR: 71–83). The median survival was 18 months (IQR: 10–31). In multivariate analysis, a statistically significant association with OS was observed with all the markers (NLR, PLR, albumin, hemoglobin, PSA decrease, reaching PSA nadir and a 50% PSA decline), except for testosterone levels. Our findings support the use of markers of systemic inflammation (NLR, PLR and albumin), hemoglobin and PSA metrics as prognostic indicators for OS in de novo mCSPC.

Download Full-text

Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study

European Urology Open Science ◽

10.1016/j.euros.2020.12.002 ◽

2021 ◽

Vol 24 ◽

pp. 1-8

Author(s):

Lise H. Omland ◽

Henriette Lindberg ◽

Andreas Carus ◽

Anne Birgitte Als ◽

Niels Viggo Jensen ◽

...

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Real World ◽

Locally Advanced ◽

Population Based ◽

Treatment Patterns ◽

Population Based Study ◽

Tract Cancer

Download Full-text

A nationwide population-based study on overall survival after meningioma surgery

Cancer Epidemiology ◽

10.1016/j.canep.2020.101875 ◽

2021 ◽

Vol 70 ◽

pp. 101875

Author(s):

Charles Champeaux-Depond ◽

Joconde Weller ◽

Sebastien Froelich ◽

Matthieu Resche-Rigon

Keyword(s):

Overall Survival ◽

Population Based ◽

Population Based Study ◽

Meningioma Surgery

Download Full-text

The risk and prognosis of secondary primary malignancy in lung cancer: a population-based study

Future Oncology ◽

10.2217/fon-2021-0045 ◽

2021 ◽

Author(s):

Jia Hong ◽

Rongrong Wei ◽

Chuang Nie ◽

Anastasiia Leonteva ◽

Xu Han ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Cox Regression ◽

Population Based ◽

Second Primary ◽

Second Primary Malignancy ◽

Risk Models ◽

Primary Malignancy ◽

Population Based Study ◽

Competing Risk Models

Aim: To assess and predict risk and prognosis of lung cancer (LC) patients with second primary malignancy (SPM). Methods: LC patients diagnosed from 1992 to 2016 were obtained through the Surveillance, Epidemiology, and End Results database. Standardized incidence ratios were calculated to evaluate SPM risk. Cox regression and competing risk models were applied to assess the factors associated with overall survival, SPM development and LC-specific survival. Nomograms were built to predict SPM probability and overall survival. Results & conclusion: LC patients remain at higher risk of SPM even though the incidence declines. Patients with SPM have a better prognosis than patients without SPM. The consistency indexes for nomograms of SPM probability and overall survival are 0.605 (95% CI: 0.598–0.611) and 0.644 (95% CI: 0.638–0.650), respectively.

Download Full-text

A Population-Based Study on the Epidemiology of Functional Gastrointestinal Disorders in Young Children

The Journal of Pediatrics ◽

10.1016/j.jpeds.2016.08.095 ◽

2016 ◽

Vol 179 ◽

pp. 139-143.e1 ◽

Cited By ~ 28

Author(s):

Ashish Chogle ◽

Carlos A. Velasco-Benitez ◽

Ilan J. Koppen ◽

Jairo E. Moreno ◽

Carmen R. Ramírez Hernández ◽

...

Keyword(s):

Young Children ◽

Functional Gastrointestinal Disorders ◽

Population Based ◽

Gastrointestinal Disorders ◽

Population Based Study

Download Full-text

Conditional Survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2020.7568 ◽

2020 ◽

Vol 18 (9) ◽

pp. 1230-1237 ◽

Cited By ~ 1

Author(s):

Seyed M. Qaderi ◽

Paul W. Dickman ◽

Johannes H.W. de Wilt ◽

Rob H.A. Verhoeven

Keyword(s):

Rectal Cancer ◽

Colon Cancer ◽

Population Based ◽

Stage I ◽

Stage Iii ◽

Disease Stage ◽

Conditional Survival ◽

Population Based Study ◽

Pathologic Stage ◽

Number Of Patients

Background: The increasing number of colorectal cancer (CRC) survivors need survival estimates that account for the time already survived. The aim of this population-based study was to determine conditional survival, cure proportions, and time-to-cure (TTC) of patients with colon or rectal cancer. Materials and Methods: All patients with pathologic stage I–III CRC treated with endoscopy or surgery, diagnosed and registered in the Netherlands Cancer Registry between 1995 and 2016, and aged 18 to 99 years were included. Conditional survival was calculated for those diagnosed before and after 2007. Cure proportions were calculated using flexible parametric models. Results: A total of 175,384 patients with pathologic stage I (25%), II (38%), or III disease (37%) were included. Conditional 5-year survival of patients with stage I, II, and III colon cancer having survived 5 years was 98%, 94%, and 92%, respectively. For patients with stage I–III rectal cancer, this was 96%, 89%, and 85%, respectively. Statistical cure in patients with colon cancer was reached directly after diagnosis (stage I) to 6 years (stage III) after diagnosis depending on age, sex, and disease stage. Patients with rectal cancer reached cure 0.5 years after diagnosis (stage I) to 9 years after diagnosis (stage III). In 1995, approximately 42% to 46% of patients with stage III colon or rectal cancer, respectively, were considered cured, whereas in 2016 this percentage increased to 73% to 78%, respectively. Conclusions: The number of patients with CRC reaching cure has increased substantially over the years. This study’s results provide valuable insights into trends of CRC patient survival and are important for patients, clinicians, and policymakers.

Download Full-text

Prevalence, identification, and interference of pain in young children with cerebral palsy: a population-based study

Disability and Rehabilitation ◽

10.1080/09638288.2019.1665719 ◽

2019 ◽

pp. 1-7 ◽

Cited By ~ 3

Author(s):

Kristina Tedroff ◽

Mirja Gyllensvärd ◽

Kristina Löwing

Keyword(s):

Cerebral Palsy ◽

Young Children ◽

Population Based ◽

Population Based Study ◽

Children With Cerebral Palsy

Download Full-text

Results of Postoperative Radiotherapy in the Treatment of 29 Uterine Sarcoma Patients

Tumori Journal ◽

10.1177/030089160308900215 ◽

2003 ◽

Vol 89 (2) ◽

pp. 183-188 ◽

Cited By ~ 3

Author(s):

Durmuş Etiz ◽

Melahat Garipağaoğrlu ◽

Emine Elmas Etiz ◽

Faruk M Köse ◽

Fulya Kayikçioğrlu ◽

...

Keyword(s):

Overall Survival ◽

Postoperative Radiotherapy ◽

Menopausal Status ◽

Disease Free Survival ◽

Uterine Sarcoma ◽

Stage I ◽

Primary Tumors ◽

Local Recurrences ◽

Number Of Patients ◽

Disease Free

Aims and background The objective of this study was to evaluate the results of surgery combined with postoperative radiotherapy (RT) in patients with uterine sarcoma in order to describe the patterns of relapse and to define prognostic factors. Methods We report on 29 patients with uterine sarcoma (US) treated from 1980 to 1995; 18 patients with primary tumors were treated with surgery and adjuvant irradiation, while 11 patients with local recurrences (LR) after previous surgical resection received only radiotherapy. We evaluated the influence of stage, histology, grade, menopausal status, total radiation dose and brachytherapy on survival. Histological diagnosis was leiomyosarcoma in 13 patients (44.8%), endometrial stromal sarcoma in 10 patients (34.5%), and mixed mesodermal tumors in six patients (20.7%). Fifteen patients presented with stage I-II disease, three with stage III, and 11 with local recurrences. External pelvic RT was administered to all patients, in five patients combined with brachytherapy. The mean total dose was 54 Gy (SE 1.78). Univariate and multivariate analyses were carried out. Results Overall survival (OS) for the stage I-III group was 61.1% at two years and 33.3% at five years (median 29 months, SE 13.79). Disease-free survival (DFS) was 55.6% at two years and 33.3% at five years. Median DFS was 26 months (SE 14.85). In LR cases, median OS was only 10 months (SE 4.5). Multivariate analysis demonstrated that stage was the only prognostic factor after RT for US. Conclusions These data suggest that postoperative and/or salvage RT has a questionable impact on disease-free and overall survival because of the lack of homogeneity of stages in the series reported in the literature; it has, however, acceptable late side effects. Prospective multicenter trials including a statistically evaluable number of patients are necessary to further clarify the role of RT treatment programs for US.

Download Full-text